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not benefit pediatric immunization. CONCLUSIONS: This is the first of this kind of
study in Iraq. The study recommended to increase the vaccine availability in public
health clinics and to increase in the father and mother’s education through media
program or through increasing the literacy. The family income or immunization
funding weren’t important because of the immunization in Iraq is free and sup-
ported by world health organization (WHO).
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OBJECTIVES: To quantify patient and physician preferences for therapeutic
tradeoffs involving efficacy, side-effect risks, and evidence uncertainty in chronic
hepatitis B (CHB) treatments. METHODS: Physicians who treat CHB patients and
adult patients with a self-reported physician diagnosis of CHB completed a web-
enabled, discrete-choice experiment survey in Germany and Turkey. Both patients
and physicians answered 12 treatment-choice questions. Each question required
evaluating a pair of hypothetical CHB medication profiles defined by years the
medicine has been studied, probability that patient’s viral load remains undetect-
able for 5 years with possible reversal of disease progression, 5-year treatment-
related risks of a fracture and renal insufficiency, and monthly medication cost.
Nested-logit and random-parameters logit models were used to estimate prefer-
ence weights for all attribute levels and the mean relative importance of each
attribute. RESULTS: A total of 158 physicians and 118 patients completed the sur-
vey in Germany. 159 physicians and 117 patients completed the survey in Turkey.
German patients ranked risk of renal insufficiency as most important while Ger-
manphyscians ranked efficacy asmost important. Turkish physicians andpatients
disagreed on the relative importance of all treatment attributes. Turkish patients
ranked years of evidence as themost important attribute,while Turkish physicians
ranked risk of renal insufficiency as most important. German physicians were
willing to accept a 0.4% greater increase in fracture risk than patients in return for
an additional year of evidence, while Turkish physicians were willing to accept a
3.2% smaller increase in fracture risk than patients for an additional year of
evidence. CONCLUSIONS: This is the first study to quantify patient and physician
preferences for CHB treatment attributes and the first study to elicit physician and
patient preferences for years of evidence. We observe different discrepancies be-
tween physician and patient preferences in Germany and Turkey. Such discrepan-
cies may interfere with optimal outcomes if not considered in patient-physician
interactions.
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OBJECTIVES: Given increasing concerns about a global influenza pandemic, the
aim of the current study was to investigate influenza vaccination rates among
high-risk adults and the general U.S population. METHODS: Data from the 2007-
20010 U.S. National Health andWellness Surveys (NHWS) were used. Demograph-
ics, comorbidities, and vaccination behavior in the past year were assessed for all
respondents, in addition to health-related quality of life (SF-12v2) and resource use
(number of emergency room visits and hospitalizations) in the past six months.
RESULTS: Overall, vaccination rates in the U.S. have steadily increased in the past
several years (2007: 30.0%; 2008: 32.8%; 2009: 34.3%; 2010: 37.0%). In 2010, 54.1% of
respondents (n40,541) were at high risk for influenza complications (e.g., over age
50, had chronic conditions such as asthma, diabetes, COPD, cardiovascular condi-
tions, or HIV/AIDS). These high-risk respondents reported significantly lower levels
of physical component summary scores (Means45.3 vs. 52.0, p.0001) and more
ER visits (Means0.22 vs. 0.17, p.0001) and hospitalizations in the past sixmonths
(Means0.15 vs. 0.07, p.0001) than low-risk respondents. Vaccination rates were
significantly higher for these high-risk respondents (48.6% vs. 23.2%, p.0001). No
high-risk subgroup reported vaccination rates higher than 67% (respondents with
kidney disease and HIV/AIDS reported vaccination rates of 66.5% and 67.3%, re-
spectively). In fact, many high-risk subgroups reported vaccination rates substan-
tially below 50% (caregivers of high-risk patients, respondents with multiple scle-
rosis, and pregnant women reported vaccination rates of 43.6%, 37.1%, and 30.5%,
respectively). CONCLUSIONS: Even as new universal recommendations issued by
the CDC may have some beneficial impact, overall vaccination rates were well
below 50% for the general U.S. population, even among certain high-risk subgroups
(e.g., pregnant women, caregivers). Greater emphasis on influenza vaccination,
particularly among high-risk patients, may have a long-term health outcome ben-
efit.
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OBJECTIVES: The antifungal market demonstrated dynamic changes with in-
creased incidence of fungal infections, resistance to traditional medications, and
entry of novel and generic therapies, which may significantly impact Medicaid
budgets for outpatient populations. Our objectives were: To describe utilization
and spending trends and to analyze the market share of antifungal agents indi-
cated for invasive fungal infections (IFI), from 1991 to 2009. METHODS: The data
source used in the study was the National Medicaid State Drug Utilization data
from 1991 to 2009, with records on outpatient prescription claims. Antifungal
agents in the study included all brand and generic drug names. Medications were
identified using National Drug Codes. Quarterly number of prescriptions and reim-
bursement amount were calculated for the descriptive trends. Market share of
spending for each drug was quantified over time. The quarterly price per prescrip-
tion was calculated by dividing the total reimbursement by the total number of
prescriptions. RESULTS: After entry of fluconazole in 1993, prescription claims for
amphotericin reduced by 95% from 1991 to 1995, and continued decreasing with
entry of lipid preparations. Prescription claims for fluconazole rose until 2004, then
declined by 25% with entry of new triazoles and echinocandins. More recently,
second generation triazoles dominated market share by 70%. Price-per-prescrip-
tion of lipid preparations of amphotericin decreased by 55%, but increased by 50%
for voriconazole. The price-per-prescription of itraconazole continuously rose
from $150-400 from 1992 to 2009. CONCLUSIONS: Increased use of lipid prepara-
tions of amphotericin may be due to improvement in adverse event profiles, con-
sequently leading to decreased demand for original formulation of amphotericin.
The decreased use of brand and generic fluconazole may be due to resistant fungi
and emergence of novel agents with broad-spectrum of activity. Itraconazole has a
niche market which contributes to its increasing price. Cost-effective decisions
appear to drive the use of antifungal agents.
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OBJECTIVES: Pegylated interferon-alpha plus ribavirin [P/R] are the standard of
care [SOC] for treating hepatitis C [HCV]. Few studies have evaluated the economic
implications associated with P/R treatment in real world practice. This study’s
objective is to quantify the correlation between P/R treatment duration and health
care costs in real-world clinical practice.METHODS: Paid claims data for 2003-2008
from a large U.S. health insurance company were used to identify 1,074 HCV pa-
tients with a minimum of two years of data following the start of P/R drug therapy
[index date]. Patients with a pre-treatment diagnosis for HIV, hepatitis B, cirrhosis,
liver cancer or a liver transplantationwere excluded. Patientswith 24-48weeks and
48 weeks of continuous P/R therapy were compared to patients with  24 weeks
of therapy. The multivariate analyses estimated the incremental effects of 24-48
and 48 weeks of P/R therapy controlling for baseline demographics, diagnostic
profile, and prescription drug profile. RESULTS: An estimated 82% of HCV patients
were viral genotype 1 based on limited available lab data. Genotype 1 patients
require 48weeks of treatment. 55.6% and 18.5% of study patients complete 24-48
weeks or 48weeks of drug therapy, respectively. Drug costs associatedwith 24-48
weeks of treatment were$9,832 [p0.0001] whichwere partially offset by savings
in medical costs of -$1,446 [p0.05] in the first year. First year drug costs for pa-
tients with 48 weeks of treatment were $25,696 [p0.0001] which was partially
offset by medical costs savings of -$5,535 [p0.05]. However, in the second year,
24-48 weeks of treatment was associated with a combined reduction in both med-
ical and prescription drug costs totaling -$7,590 [p0.05]. Patients achieving 48
weeks of treatment experienced a reduction in total second-year costs of -$9,334
[p0.05]. CONCLUSIONS: A full course of P/R therapy may reduce total cost over
time.
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OBJECTIVES: Pakistan is one of the four countries around the world harboring
polio. Government of Pakistan is spending lot of resources to eradicated polio in the
form of EPI (Extended Program of Immunization) initiated in 1994. The aim of our
study is to determine whether this government funded polio control program has
any impact on knowledge, attitude and perception of polio in general community.
METHODS: A cross sectional study was conducted. 477 respondents aged between
25 to 60 yearswere selected bymultistage stratified systematic sampling. KAPwere
assessed through self administered questionnaire which was developed and vali-
dated before administering to respondents. Statistical analysis was done by SPSS
16.RESULTS: 225 (47%) respondentswere female and 252 (53%)weremale.Majority
of respondents (95.4%) have heard about polio and 96.9%were of opinion that every
child must be vaccinated against polio. 27.3% of respondents believed that it is
sufficient to vaccinate a child once in life against polio. 85.1% of subject were not
aware that whether it is communicable or non-communicable disease. 31.5% of
respondents showed confidence in the capability of polio vaccination team about
providing appropriate information. 48.3% of respondents were satisfied from the
awareness campaigns of the government propagated through mass media about
polio, its prevention and timing of vaccination. CONCLUSIONS: Government is
spending lot of money on EPI but appropriate knowledge, positive attitudes and
perceptionswere found in smaller proportion of participants. This study points out
that there is need to maximize education programs to make general public aware
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